Who owns ARCA biopharma?

Key details on ARCA biopharma (Ticker: ABIO)

Who owns ARCA biopharma?

Is ABIO a good stock to own? Find out who bought ARCA biopharma, who sold ARCA biopharma (ABIO) stock, and who holds a large position in ARCA biopharma.

Fund Name Number of Shares Share Valuation As Of
Renaissance Technologies 175500 $66690 Dec. 31, 2012
Knight Capital 84997 $39098 June 30, 2012
GRT Capital Partners 71450 $65019 March 31, 2012
Vanguard 61940 $24776 Dec. 31, 2012
Bank of America Corporation 50235 $0 Dec. 31, 2012
T. Rowe Price Associates 28765 $10067 Sept. 30, 2012
Geode Capital Management 20234 $8093 Dec. 31, 2012
Oppenheimer & Co 15000 $7050 Dec. 31, 2012
Stafford Asset Management 13566 $43004 Dec. 31, 2010
UBS AG 13403 $5093 Dec. 31, 2012
CalPERS 12575 $5030 Dec. 31, 2012
Buckingham Asset Management 10220 $3985 Sept. 30, 2012
Public Employees' Retirement Association of Colorado 2575 $3012 Dec. 31, 2011
KBC Group NV 350 $0 March 31, 2012
Inves 118 $0 Sept. 30, 2012
Wells Fargo & Company 16 $0 June 30, 2012
Dan Callahan 15 $15 Dec. 31, 2011

Who sold ARCA biopharma?

Fund Name Date Sold Number of Shares Sold Share Valuation
Ladenburg Thalmann Financial Services Dec. 31, 2011 100 $100
Royal Bank of Canada Sept. 30, 2011 1000 $1000
FIRST NEW YORK SECURITIES June 30, 2011 35000 $56000
Ameriprise Financial June 30, 2011 100 $115
D. E. Shaw & Co March 31, 2011 21584 $55039
Barclays March 31, 2011 8884 $23009
AXA March 31, 2011 1300 $3315
Johnson Financial March 31, 2011 39 $75